New hope for aggressive lymphoma: drug combo trial launches
NCT ID NCT07348575
First seen Jan 19, 2026 · Last updated May 08, 2026 · Updated 21 times
Summary
This study tests whether adding decitabine to standard chemotherapy (R-CHOP) works better for people with a rare, virus-linked lymphoma (EBV+ DLBCL). About 80 newly diagnosed adults will be randomly assigned to get either the new combo or standard treatment. The main goal is to see if the new combo helps keep the cancer from coming back for 2 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE-CELL, DIFFUSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330000, China
Conditions
Explore the condition pages connected to this study.